Molecular and pharmacological evidence for MT 1 melatonin receptor subtype in the tail artery of juvenile Wistar rats

Authors:

Abstract
In this study reverse transcriptase‐polymerase chain reaction (RT–PCR) has been used to identify mt 1 and MT 2 receptor mRNA expression in the rat tail artery. The contributions of both receptors to the functional response to melatonin were examined with the putative selective MT 2 receptor antagonists, 4‐phenyl‐2‐propionamidotetraline (4‐P‐PDOT) and 2‐benzyl‐ N ‐pentanoyltryptamine. In addition, the action of melatonin on the second messenger cyclic AMP was investigated. Using RT–PCR, mt 1 receptor mRNA was detected in the tail artery from seven rats. In contrast MT 2 receptor mRNA was not detected even after nested PCR. At low concentrations of the MT 2 selective ligands, neither 10 n M 4‐P‐PDOT (pEC 50 =8.70±0.31 (control) vs 8.73±0.16, n =6) nor 60 n M 2‐benzyl‐ N ‐pentanoyltryptamine (pEC 50 =8.53±0.20 (control) vs 8.83±0.38, n =6) significantly altered the potency of melatonin in the rat tail artery. At concentrations non‐selective for mt 1 and MT 2 receptors, 4‐P‐PDOT (3 μ M ) and 2‐benzyl‐ N ‐pentanoyltryptamine (5 μ M ) caused a significant rightward displacement of the vasoconstrictor effect of melatonin. In the case of 4‐P‐PDOT, the estimated pK B (6.17±0.16, n =8) is similar to the binding affinity for mt 1 receptor. Pre‐incubation with 1 μ M melatonin did not affect the conversion of [ 3 H]‐adenine to [ 3 H]‐cyclic AMP under basal condition (0.95±0.19% conversion (control) vs 0.92±0.19%, n =4) or following exposure to 30 μ M forskolin (5.20±1.30% conversion (control) vs 5.35±0.90%, n =4). Based on the above findings, we conclude that melatonin receptor on the tail artery belongs to the MT 1 receptor subtype, and that this receptor is probably independent of the adenylyl cyclase pathway. British Journal of Pharmacology (1999) 127 , 987–995; doi: 10.1038/sj.bjp.0702612

This publication has 26 references indexed in Scilit: